Novel topical formulations for treatment of dental diseases
Orapharma is a specialty pharmaceuticals company focusing on developing and commercializing novel therapeutics to improve and maintain oral health. The company developed ARESTIN, an oral topical formulation of minocycline, that was approved by the FDA in 2001 for treatment of periodontal disease. Orapharma completed its IPO in 2000 and was acquired by J&J in 2002.
